CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy

Summary

This pilot clinical trial studies 6, 8-bis (benzylthio) octanoic acid (CPI-613) in treating patients with myelodysplastic syndromes who failed previous therapy. Sometimes when chemotherapy or biological therapy is given, it does not stop the growth of tumor cells. The tumor is said to be resistant to treatment. 6, 8-bis (benzylthio) octanoic acid may interfere with the growth of tumor cells and may be an effective treatment for myelodysplastic syndromes that did not respond to previous therapy.

Timeline

Start

2013-08

Primary completion

2018-11-26

Completion

2018-11-26

Drugs

Indications